Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | TL-895 |
Synonyms | |
Therapy Description |
TL-895 is a tyrosine kinase inhibitor that binds to tyrosine kinases in tumor cells, potentially leading to inhibition of tumor cell proliferation, tumor angiogenesis, and inflammatory immune response (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
TL-895 | TL895|TL 895 | TL-895 is a tyrosine kinase inhibitor that binds to tyrosine kinases in tumor cells, potentially leading to inhibition of tumor cell proliferation, tumor angiogenesis, and inflammatory immune response (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04878003 | Phase II | TL-895 KRT-232 | Study of KRT-232 or TL-895 in Janus Associated Kinase Inhibitor Treatment-Naive Myelofibrosis | Recruiting | USA | POL | BGR | 6 |
NCT02825836 | Phase Ib/II | TL-895 | Phase I/II, First in Human, Dose Escalation Trial of TL 895 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia or Relapsed/Refractory Small Lymphocytic Lymphoma | Active, not recruiting | USA | POL | ITA | HUN | GBR | 2 |
NCT04655118 | Phase II | TL-895 | Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis | Recruiting | USA | POL | ITA | HUN | FRA | ESP | DEU | BRA | BGR | BEL | AUS | 2 |